Comorbidity in patients with Lichen sclerosus: a retrospective cohort study
Tóm tắt
Lichen sclerosus (LS) is a chronic lymphocyte mediated inflammatory mucocutaneous disease of unknown aetiology with a predilection for the anogenital region, and affecting both sexes. The disease is characterized by pain, intolerable itching and scarring. In late stages of LS, disfiguring scarring can drastically alter the structural anatomical architecture of the genitals. The association between genital LS and different malignant tumours is a concern that needs to be further investigated. An association between LS and several autoimmune diseases has been confirmed in recent studies. All registered citizens of Region Jönköping, Sweden were included in the present study. Patients diagnosed with LS (n = 5680) between 2001 and 2021 were identified using ICD-10 code L90.0 and selected as cases. All other individuals (n = 362 568) served as controls. Odds ratios (ORs) for the selected comorbidity were calculated and adjusted for age and sex. The cumulative incidence of LS for the entire population over a 20-year period was 1.54% (15.4 per 1000 people). The cumulative incidences over a 20-year period for females and males were 2.13% and 0.97%, respectively. This study confirmed the association between LS and vulvar cancer (OR = 17.4; 95% CI 12.1–25.3), penis cancer (OR = 9.1; 95% CI 4.3–18.9), prostate cancer (OR = 2.0; 95% CI 1.6–2.4) and breast cancer (OR = 1.6; 95% CI 1.4–1.8). LS was also associated with Crohn´s disease (OR = 2.0; 95% CI 1.6–2.6) and diabetes mellitus type 1 (OR = 1.9; 95% CI 1.6–2.1). The present study revealed novel important data regarding the association of LS with cancer and autoimmune diseases, emphasising the importance of sufficient treatment and follow-up of patients with LS. However, future studies are needed to confirm these results and the potential role of LS in the development of cancer.
Tài liệu tham khảo
Kirtschig G. Lichen sclerosus-presentation diagnosis and management. Dtsch Arztebl Int. 2016;113(19):337–43.
Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. Lichen Sclerosus: An autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int J Biol Sci. 2019;15(7):1429–39.
Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: a scoping review. Obstet Gynecol Int. 2020;2020:7480754.
Kwok R, Shah TT, Minhas S. Recent advances in understanding and managing Lichen Sclerosus. F1000Res. 2020. https://doi.org/10.12688/f1000research.21529.1.
Spekreijse JJ, Streng BMM, Vermeulen RFM, Voss FO, Vermaat H, van Beurden M. The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: a systematic review. Gynecol Oncol. 2020;157(3):671–7.
Chan I, Oyama N, Neill SM, Wojnarowska F, Black MM, McGrath JA. Characterization of IgG autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Clin Exp Dermatol. 2004;29(5):499–504.
Sherman V, McPherson T, Baldo M, Salim A, Gao XH, Wojnarowska F. The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study. J Eur Acad Dermatol Venereol. 2010;24(9):1031–4.
Pass CJ. An unusual variant of lichen sclerosus et atrophicus: delayed appearance in a surgical scar. Cutis. 1984;33(4):405–8.
Yates VM, King CM, Dave VK. Lichen sclerosus et atrophicus following radiation therapy. Arch Dermatol. 1985;121(8):1044–7.
Milligan A, Graham-Brown RA, Burns DA. Lichen sclerosus et atrophicus following sunburn. Clin Exp Dermatol. 1988;13(1):36–7.
Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol. 2018;178(4):839–53.
Le Cleach L, Chosidow O. Clinical practice Lichen planus. N Engl J Med. 2012;366(8):723–32.
Murphy R. Lichen sclerosus. Dermatol Clin. 2010;28(4):707–15.
Bleeker MC, Visser PJ, Overbeek LI, van Beurden M, Berkhof J. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2016;25(8):1224–30.
Hakenberg OW, Comperat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142–50.
Eberz B, Berghold A, Regauer S. High prevalence of concomitant anogenital lichen sclerosus and extragenital psoriasis in adult women. Obstet Gynecol. 2008;111(5):1143–7.
Bjekić M, Šipetić S, Marinković J. Risk factors for genital lichen sclerosus in men. Br J Dermatol. 2011;164(2):325–9.
Howard M, Hall A. Vulval lichen planus-lichen sclerosus overlap. Int J STD AIDS. 2018;29(10):1017–23.
Yalici-Armagan B, Bostan E, Akdogan N, Ersoy-Evans S. Paediatric lichen sclerosus et atrophicus: a retrospective analysis of 38 paediatric patients. Int J Clin Pract. 2021;75(10): e14661.
Soderlund JM, Hieta NK, Kurki SH, Orte KJ, Polo-Kantola P, Hietanen SH, et al. Comorbidity of urogynecological and gastrointestinal disorders in female patients with lichen sclerosus. J Low Genit Tract Dis. 2023;27(2):156–60.
Prasad S, Black SM, Zhu JL, Sharma S, Jacobe H. Morphea patients with mucocutaneous involvement: A cross-sectional study from the Morphea in Adults and Children (MAC) cohort. J Am Acad Dermatol. 2021;85(1):114–20.
Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol. 2005;53(4):555–68.
Hakenberg OW, Dräger DL, Erbersdobler A, Naumann CM, Jünemann KP, Protzel C. The Diagnosis and treatment of penile cancer. Dtsch Arztebl Int. 2018;115(39):646–52.
Halonen P, Jakobsson M, Heikinheimo O, Riska A, Gissler M, Pukkala E. Lichen sclerosus and risk of cancer. Int J Cancer. 2017;140(9):1998–2002.
Hieta N, Rintala M, Söderlund JM, Samu K, Orte K, Hietanen S. Comorbidity of dermal and cardiovascular disorders with lichen sclerosus: a case-control study. Acta Derm Venereol. 2021;101(11):adv00594.
Virgili A, Borghi A, Cazzaniga S, Di Landro A, Naldi L, Minghetti S, et al. New insights into potential risk factors and associations in genital lichen sclerosus: data from a multicentre Italian study on 729 consecutive cases. J Eur Acad Dermatol Venereol. 2017;31(4):699–704.
Fan R, Leasure AC, Maisha FI, Cohen JM, Little AJ. Thyroid disorders associated with lichen sclerosus: a case-control study in the All of Us Research Program. Br J Dermatol. 2022. https://doi.org/10.1111/bjd.21702.
Kreuter A, Kryvosheyeva Y, Terras S, Moritz R, Möllenhoff K, Altmeyer P, et al. Association of autoimmune diseases with lichen sclerosus in 532 male and female patients. Acta Derm Venereol. 2013;93(2):238–41.
Auböck J, Romani N, Grubauer G, Fritsch P. HLA-DR expression on keratinocytes is a common feature of diseased skin. Br J Dermatol. 1986;114(4):465–72.
Eisendle K, Grabner T, Kutzner H, Zelger B. Possible role of Borrelia burgdorferi sensu lato infection in lichen sclerosus. Arch Dermatol. 2008;144(5):591–8.
Kirtschig G, Becker K, Gunthert A, Jasaitiene D, Cooper S, Chi CC, et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. J Eur Acad Dermatol Venereol. 2015;29(10):e1-43.
Goussot R, Francès C, Cury K, Bessis D, Martin T, Chatelus E, et al. Prospective evaluation of the frequency of genital lichen sclerosus in 79 patients with systemic sclerosis. Br J Dermatol. 2018;179(4):999–1000.